Determination of a peroxisome proliferator-activated receptor γ agonist, 1-(trans-methylimino-N-oxy)-6-(2-morpholinoethoxy-3-phenyl-1H-indene-2-carboxylic acid ethyl ester (KR-62980) in rat plasma by liquid chromatography-tandem mass spectrometry

Journal of Pharmaceutical and Biomedical Analysis

Volumn 54, Issue 1, 2011, Pages 121-126

  Kim, Min Sun ^a   Song, Jin Sook ^a   Roh, Hyeongjin ^a   Park, Jong Shik ^a   Ahn, Jin Hee ^a   Ahn, Sung Hoon ^a   Bae, Myung Ae ^a  

^a Korea Research Institute of Chemical Technology   (South Korea)

Author keywords

KR 62980; LC MS MS; Method validation; Pharmacokinetics; Rat plasma

Indexed keywords

1 (TRANS METHYLIMINO N OXY) 6 (2 MORPHOLINOETHOXY 3 PHENYL 1H INDENE 2 CARBOXYLIC ACID ETHYLESTER; ACETIC ACID ETHYL ESTER; ACETONITRILE; AMMONIUM FORMATE; IMIPRAMINE; KR 62980; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; UNCLASSIFIED DRUG;

ACCURACY; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STABILITY; DRUG STRUCTURE; ELECTROSPRAY; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; MALE; MASS SPECTROMETRY; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; REPRODUCIBILITY; SENSITIVITY ANALYSIS;

ACETONITRILES; ANIMALS; AREA UNDER CURVE; CALIBRATION; CHEMISTRY TECHNIQUES, ANALYTICAL; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; FORMIC ACIDS; INDENES; MASS SPECTROMETRY; MODELS, CHEMICAL; MORPHOLINES; PPAR GAMMA; QUALITY CONTROL; RATS; REPRODUCIBILITY OF RESULTS;

EID: 77957021259     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2010.07.033     Document Type: Article

References (18)

1. Calnek D.S., Mazzella L., Roser S., Roman J., Hart C.M. Peroxisome proliferator-activated receptor γ ligands increase release of nitric oxide from endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2003, 23:52-57.
2. Odegaard J.I., Ricardo-Gonzalez R.R., Goforth1 M.H., Morel1 C.R., Subramanian Vi., Mukundan L., Eagle A.R., Vats D., Brombacher F., Ferrante A.W., Chawla A. Macrophage-specific PPARc controls alternative activation and improves insulin resistance. Nature 2007, 447:1116-1121.
3. Chui P.C., Guan H., Lehrke Mi., Lazar M.A. PPARγ regulates adipocyte cholesterol metabolism via oxidized LDL receptor 1. J. Clin. Invest. 2005, 115:2244-2256.
4. Rangwala S.M., Rhoades B., Shapiro J.S., Rich A.S., Kim J.K., Shulman G.I., Kaestner K.H., Lazar M.A. Genetic modulation of PPARγ phosphorylation regulates insulin sensitivity. Dev. Cell. 2003, 5:657-663.
5. Brown K.K., Henke B.R., Blanchard S.G., Cobb J.E., Mook R., Kaldor I., Kliewer S.A., Lehmann J.M., Lenhard J.M., Harrington W.W., Novak P.J., Faison W., Binz J.G., Hashim M.A., Oliver W.O., Brown H.R., Parks D.J., Plunket K.D., Tong W., Menius J.A., Adkison K., Noble S.A., Willson T.M. A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-γ reverses the diabetic phenotype of the Zucker diabetic fatty rat. Diabetes 1999, 48:1415-1424.
6. Adams M., Montague C.T., Prins J.B., Holder J.C., Smith St.A., Sanders L., Digby J.E., Sewter C.P., Lazar M.A., Chatterjee V.K.K., O'Rahilly S. Activators of peroxisome proliferator-activated receptor γ have depot-specific effects on human preadipocyte differentiation. J. Clin. Invest. 1997, 100:3149-3153.
7. Ye J., Doyle P.J., Iglesias M.A., Watson D.G., Cooney G.J., Kraegen E.W. Peroxisome proliferator-activated receptor (PPAR)-α activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats. Diabetes 2001, 50:411-417.
8. Kim K.R., Lee J.H., Kim S.J., Rhee S.D., Jung W.H., Yang S., Kim S.S., Ahn J.H., Cheon H.G. KR-62980: a novel peroxisome proliferator-activated receptor γ agonist with weak adipogenic effects. Biochem. Pharmacol. 2006, 72:446-454.
9. Jung H., Lee M.S., Jang E.J., Ahn J.H., Kang N.S., Yoo S., Bae M.A., Hong J., Hwang E.S. Augmentation of PPARγ-TAZ interaction contributes to the anti-adipogenic activity of KR62980. Biochem. Pharmacol. 2009, 78:1323-1329.
10. Cwika M.J., Wua H., Muzzioa M., McCormicka D.L., Kapetanovicb I. Direct quantitation of glucoraphanin in dog and rat plasma by LC-MS/MS. J. Pharm. Biomed. Anal. 2010, 52:544-549.
11. Wena J., Hong Z., Wua Y., Wei H., Fan G., Wu Y. Simultaneous determination of rupatadine and its metabolite desloratadine in human plasma by a sensitive LC-MS/MS method: Application to the pharmacokinetic study in healthy Chinese volunteers. J. Pharm. Biomed. Anal. 2009, 49:347-353.
12. Bhaumik U., Ghosh A., Sarkar A.K., Bose A., Selvan P.S., Sengupta P., Chakraborty U.S., Ghosh D., Kumar Pal T. Determination of ranolazine in human plasma by LC-MS/MS and its application in bioequivalence study. J. Pharm. Biomed. Anal. 2008, 48:1404-1410.
13. Srinivas N.R. Applicability of bioanalysis of multiple analytes in drug discovery and development: review of select case studies including assay development considerations. Biomed. Chromatogr. 2006, 20:383-414.
14. Hopfgartner G., Bourgogne E. Quantitative high-throughput analysis of drugs in biological matrices by mass spectrometry. Mass Spectrom. Rev. 2003, 22:195-214.
15. + exchanger inhibitor, 4-cyano(benzo[b]thiophene-2-carbonyl)guanidine (KR-33028) in rat plasma by liquid chromatography-tandem mass spectrometry. Biomed. Chromatogr. 2007, 21:810-815.
16. Kitteringhama N.R., Jenkinsa R.E., Laneb C.S., Elliott V.L., Parka B.K. Multiple reaction monitoring for quantitative biomarker analysis in proteomics and metabolomics. J. Chromatogr. B 2009, 877:1229-1239.
17. Di L., Kerns E.H., Hong Y., Chen H. Development and application of high throughput plasma stability assay for drug discovery. Int. J. Pharm. 2005, 297:110-119.
18. Di L., Kerns E.H. Solution stability - plasma, gastrointestinal, bioassay. Curr. Drug Metab. 2008, 9:860-868.